The importance of the tumor immune microenvironment, and particularly the T cell microenvironment, in cSCC is underscored by the fact that PD-1 checkpoint inhibition results in tumor regression in immunocompetent patients, even those with metastatic disease3–5. This evidence concerns the gene PDCD1 and neoplasm.